Sweta Chakraborty | Why is Communicating Pharmaceutical Risks and Benefits So Hard?
21904
post-template-default,single,single-post,postid-21904,single-format-standard,ajax_fade,page_not_loaded,,select-child-theme-ver-1.0.0,select-theme-ver-2.0,vertical_menu_enabled, vertical_menu_transparency vertical_menu_transparency_on,wpb-js-composer js-comp-ver-4.4.4,vc_responsive

Why is Communicating Pharmaceutical Risks and Benefits So Hard?

Pharmaceuticals are developed for patients who behave according to perceptions, not just facts, about medicines. How should we respond to demands for higher quality information, greater openness and transparency with round-the-clock media scrutiny? What is the role of trust and how can we strengthen trustworthiness in communication? How should the evidence behind good communication impact regulatory processes? How can we assess whether communication is effective in changing behavior? Questions like these will be discussed in a forum held as part of the Drug Information Association’s (DIA) annual meeting in Washington DC June 14-18 as we aim to address this core risk minimization activity for any pharmaceutical organization.  Further details for the meeting and my talk can be seen at: Dia Annual Meeting

No Comments

Post a Comment